RETRACTION: "Effect of PLK1 Inhibition on Cisplatin-resistant Gastric Cancer Cells".
Z. Chen, Y. Chai, T. Zhao, P. Li, L. Zhao, F. He, Y. Lang, J. Qin, H. Ju, "Effect of PLK1 Inhibition on Cisplatin-resistant Gastric Cancer Cells," Journal of Cellular Physiology 234, no. 5 (2019): 5904-5914, https://doi.org/10.1002/jcp.26777. The above article, published online on 29 November 2018 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors; the journal Editor-in-Chief, Alexander Hutchison; and Wiley Periodicals LLC. The retraction has been agreed upon the authors' request. After the publication of their article, the authors discovered that the cell lines BGC-823 and SGC-7901 used in their study have been reported as contaminated [1, 2]. The authors have contacted the journal requesting the retraction of their article as these issues compromise the reliability of the research presented. The retraction is warranted, as the editors concur with the authors that the data is unreliable and the conclusions are invalid. REFERENCES [1] F. Ye, C. Chen, J. Qin, J. Liu, C. Zheng, "Genetic Profiling Reveals an Alarming Rate of Cross-contamination among Human Cell Lines Used in China," The FASEB Journal 29, no. 10 (2015): 4268-4272, https://doi.org/10.1096/fj.14-266718 [2] X. Bian, Z. Yang, H. Feng, H. Sun, Y. Liu, "A Combination of Species Identification and STR Profiling Identifies Cross-contaminated Cells from 482 Human Tumor Cell Lines," Scientific Reports 7, no. 1 (2017): 9774, https://doi.org/10.1038/s41598-017-09660-w.
《-》
Retraction statement: Ding, J., Wang, X., Gao, J. and Song, T. (2021), Silencing of cystatin SN abrogates cancer progression and stem cell properties in papillary thyroid carcinoma. FEBS Open Bio, 11: 2186-2197.
https://doi.org/10.1002/2211-5463.13221 The above article, published online on 08 June 2021 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the Editor-in-Chief Miguel De la Rosa, FEBS Press, and John Wiley and Sons Ltd. The retraction has been agreed following an investigation into concerns raised by a third party, which revealed inappropriate duplications between this and articles that were either previously published or published later in the same year [1-9]. Thus, the editors consider the conclusions of this manuscript substantially compromised. [1] Zheng, X., Huang, M., Xing, L. et al. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer. Mol Cancer 19, 73 (2020). https://doi.org/10.1186/s12943-020-01183-9. [2] Li X, Wang H, Liu Z, Abudureyimu A. CircSETD3 (Hsa_circ_0000567) Suppresses Hepatoblastoma Pathogenesis via Targeting the miR-423-3p/Bcl-2-Interacting Mediator of Cell Death Axis. Front Genet. 2021 Sep 29;12:724197. doi: 10.3389/fgene.2021.724197. PMID: 34659347; PMCID: PMC8511783. [3] Du J, Zhong H, Ma B. Targeting a novel LncRNA SNHG15/miR-451/c-Myc signaling cascade is effective to hamper the pathogenesis of breast cancer (BC) in vitro and in vivo. Cancer Cell Int. 2021 Mar 31;21(1):186. doi: 10.1186/s12935-021-01885-0. PMID: 33952250; PMCID: PMC8097789. [4] Hong W, Xue M, Jiang J, Zhang Y, Gao X. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res. 2020 Aug 3;39(1):149. doi: 10.1186/s13046-020-01648-1. PMID: 32746878; PMCID: PMC7397626. [5] Ren N, Jiang T, Wang C, Xie S, Xing Y, Piao D, Zhang T, Zhu Y. LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis. Aging (Albany NY). 2020 Jun 9;12(11):11025-11,041. doi: 10.18632/aging.103314. Epub 2020 Jun 9. PMID: 32516127; PMCID: PMC7346038. [6] Zheng Y, Liu L, Wang Y, Xiao S, Mai R, Zhu Z, Cao Y. Glioblastoma stem cell (GSC)-derived PD-L1-containing exosomes activates AMPK/ULK1 pathway mediated autophagy to increase temozolomide-resistance in glioblastoma. Cell Biosci. 2021 Mar 31;11(1):63. doi: 10.1186/s13578-021-00575-8. PMID: 33789726; PMCID: PMC8011168. [7] Lin H, Wang J, Wang T, Wu J, Wang P, Huo X, Zhang J, Pan H, Fan Y. The LncRNA MIR503HG/miR-224-5p/TUSC3 Signaling Cascade Suppresses Gastric Cancer Development via Modulating ATF6 Branch of Unfolded Protein Response. Front Oncol. 2021 Jul 26;11:708501. doi: 10.3389/fonc.2021.708501. PMID: 34381729; PMCID: PMC8352579. [8] Lu G, Li Y, Ma Y, Lu J, Chen Y, Jiang Q, Qin Q, Zhao L, Huang Q, Luo Z, Huang S, Wei Z. Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/E2F1/Nanog axis. J Exp Clin Cancer Res. 2018 Nov 27;37(1):289. doi: 10.1186/s13046-018-0945-6. PMID: 30482236; PMCID: PMC6260744. [9] Zhao Y, Zheng R, Chen J, Ning D. CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC). Cancer Cell Int. 2020 Jul 6;20:289. doi: 10.1186/s12935-020-01390-w. PMID: 32655321; PMCID: PMC7339514.
《FEBS Open Bio》
RETRACTION: Long Noncoding RNA UFC1 is Activated by E2F1 and Exerts Oncogenic Properties by Functioning as a CeRNA of FOXP3.
J. Xi, J. Feng, S. Zeng, and P. Huang, "Long Noncoding RNA UFC1 is Activated by E2F1 and Exerts Oncogenic Properties by Functioning as a CeRNA of FOXP3," Cancer Medicine 7, no. 7 (2018): 3301-3310. https://doi.org/10.1002/cam4.1556. The above article, published online on 23 May 2018 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Stephen Tait; and John Wiley and Sons Ltd. The retraction has been agreed following an investigation into concerns raised by a third party, which revealed inappropriate duplications of image panels (Figure 3A-C, Figure 4C (HeLa-FOXP3 and GAPDH lanes) and D (FOXP3 lane)) between this and another article previously published by a different group of authors, in a different scientific context, elsewhere. Given the extent of the identified issues, the editors have lost confidence in the data presented and the article's conclusions can no longer be considered reliable. The authors have been informed of the allegations and the decision to retract but they remained unresponsive.
《Cancer Medicine》
RETRACTION: Selection for TRAIL Resistance Results in Melanoma Cells with High Proliferative Potential.
J. J. Wu, X. D. Zhang, S. Gillespie, and P. Hersey, "Selection for TRAIL Resistance Results in Melanoma Cells with High Proliferative Potential," FEBS Letters 579, no. 9 (2005): 1940-1944, https://doi.org/10.1016/j.febslet.2005.02.041. The above article, published online on February 25, 2005, in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Michael Brunner; FEBS Press; and John Wiley and Sons Ltd. The retraction has been agreed upon following an investigation into concerns raised by a third party, which revealed inappropriate duplications of image sections within the article (Fig. 2A, 3A-C, 4A-B) depicting different experimental conditions. The authors were unable to provide a satisfactory explanation and due to the elapsed time the raw data was not available. Given the extent of the identified issues, the editors have lost confidence in the data presented and the article's conclusions can no longer be considered reliable.
《-》
ResearchGate
(全网免费下载)
钛学术
(全网免费下载)
